Common Wart Clinical Trial
Official title:
Efficacy of Cryotherapy Combined With Intralesional Tuberculin Purified Protein Derivative (PPD) Versus Interlesional Tuberculin PPD Monotherapy in the Treatment of Multiple Common Warts
The investigate the efficacy and safety of combined 'cryo-immuno-therapy' versus intralesional tuberculin purified protein derivative (PPD) antigen immunotherapy alone for multiple common warts
Common warts are benign skin lesions caused by the human papillomavirus (HPV). The dorsal
surface of the hands and fingers are the main predilection sites. Cryotherapy is frequently
used to eradicate common warts via necrotic destruction of HPV-infected keratinocytes or by
inducing of an effective cell-mediated immune response. However, the cure rates of
cryotherapy are only around (44-47%) .
Intralesional antigen immunotherapy represents a promising therapeutic approach for the
treatment of different types of warts, particularly if multiple and/or recalcitrant.
The investigate the efficacy and safety of combined 'cryo-immuno-therapy' versus
intralesional tuberculin purified protein n immunotherapy alone for multiple common warts.
Although intralesional immunotherapy - compared to conventional therapeutic methods - has
been generally along with better outcome, lower incidence of side effects and less
recurrence, it is not still approved as a standard method of treatment in patients with wart
, because the majority of available studies are open-labeled and randomized,
placebo-controlled trials are very scarce.
The immune system plays an important role in the spontaneous resolution of warts. The immune
mechanisms against HPV include the development of cell-mediated immune response with
activation of T helper1 (Th1) lymphocytes resulting in long-term immunity . Stimulation of
the immune system would clear warts in other locations, eliminating the need for the local
treatment for each individual wart .
Multiple studies support the use of intralesional PPD injection as an effective and valuable
treatment option due to its systemic effect, especially for patients with multiple warts,
with the benefit of clearance of both treated and distant warts.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT01796795 -
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
|
Phase 2 | |
| Completed |
NCT03687372 -
Study of A-101 Topical Solution for the Treatment of Common Warts
|
Phase 3 | |
| Completed |
NCT03691831 -
A Study of A-101 Topical Solution for the Treatment of Common Warts
|
Phase 3 | |
| Completed |
NCT00328991 -
Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts
|
N/A | |
| Completed |
NCT05115669 -
Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts
|
N/A | |
| Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 | |
| Active, not recruiting |
NCT05896215 -
OM202JP Clinical Study of KNP2002
|
Phase 2 | |
| Completed |
NCT03278028 -
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
|
Phase 2 | |
| Completed |
NCT03812510 -
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
|
Phase 3 | |
| Recruiting |
NCT05799157 -
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
|
Phase 2 | |
| Recruiting |
NCT06214559 -
Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts.
|
N/A | |
| Recruiting |
NCT03977753 -
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
|
Phase 4 | |
| Completed |
NCT03210337 -
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
|
Phase 2 | |
| Completed |
NCT03183765 -
Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts
|
Phase 4 |